Advertisement

Journal of Medical Toxicology

, Volume 10, Issue 1, pp 26–39 | Cite as

A Review of the Toxicity of HIV Medications

  • Asa M. Margolis
  • Harry Heverling
  • Paul A. Pham
  • Andrew StolbachEmail author
Review Article

Abstract

Antiretroviral therapy has changed human immunodeficiency virus (HIV) infection from a near-certainly fatal illness to one that can be managed chronically. More patients are taking antiretroviral drugs (ARVs) for longer periods of time, which naturally results in more observed toxicity. Overdose with ARVs is not commonly reported. The most serious overdose outcomes have been reported in neonates who were inadvertently administered supratherapeutic doses of HIV prophylaxis medications. Typical ARV regimens include a “backbone” of two nucleoside reverse transcriptase inhibitors (NRTI) and a “base” of either a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor. New classes of drugs called entry inhibitors and integrase inhibitors have also emerged. Older NRTIs were associated with mitochondrial toxicity, but this is less common in the newer drugs, emtricitabine, lamivudine, and tenofovir. Mitochondrial toxicity results from NRTI inhibition of a mitochondrial DNA polymerase. Mitochondrial toxicity manifests as myopathy, neuropathy, hepatic failure, and lactic acidosis. Routine lactate assessment in asymptomatic patients is not indicated. Lactate concentration should be obtained in patients taking NRTIs who have fatigue, nausea, vomiting, or vague abdominal pain. Mitochondrial toxicity can be fatal and is treated by supportive care and discontinuing NRTIs. Metabolic cofactors like thiamine, carnitine, and riboflavin may be helpful in managing mitochondrial toxicity. Lipodystrophy describes changes in fat distribution and lipid metabolism that have been attributed to both PIs and NRTIs. Lipodystrophy consists of loss of fat around the face (lipoatrophy), increase in truncal fat, and hypertriglyceridemia. There is no specific treatment of lipodystrophy. Clinicians should be able to recognize effects of chronic toxicity of ARVs, especially mitochondrial toxicity.

Keywords

Antiretroviral Mitochondrial toxicity NRTI Toxicity HIV Overdose ART HART Protease inhibitor NNRTI Nonnucleoside reverse transcriptase inhibitor Nucleoside reverse transcriptase inhibitor Mitochondrial toxicity Lactic acidosis Tenofovir Stavudine Lamivudine Emtricitabine Didanosine Abacavir Zalcitabine Zidovudine Nevirapine Efavirenz Etravirine Delavirdine Maraviroc Raltegravir Enfuvirtide 

Notes

Conflicts of Interest

Dr. Stolbach owns stock in Gilead Pharmaceuticals (see Universal COI form). No other conflicts are reported.

References

  1. 1.
    Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P et al (2012) Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308(4):387PubMedGoogle Scholar
  2. 2.
    Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D’Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team (2003) Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349(24):2304PubMedGoogle Scholar
  3. 3.
    Parienti JJ, Bangsberg DR, Verdon R, Gardner EM (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 48(4):484–488PubMedCentralPubMedGoogle Scholar
  4. 4.
    Maignen F, Meglio S, Bidault I, Castot A (1993) Acute toxicity of zidovudine. Analysis of the literature and number of cases at the Paris Poison Control Center. Therapie 48(2):129–31PubMedGoogle Scholar
  5. 5.
    Livshits Z, Lee S, Hoffman RS, Nelson LS, Esteban-Cruciani N (2011) Zidovudine (AZT) overdose in a healthy newborn receiving postnatal prophylaxis. Clin Toxicol (Phila) 49(8):747–9, Epub 2011 Aug 25Google Scholar
  6. 6.
    Chiappini E, Galli L, Gabiano C, Gattinara GC, Martino A, Scolfaro C et al (2008) Preventable zidovudine overdose during postnatal prophylaxis in healthy children born to HIV-1-positive mothers. AIDS 22(2):316–7PubMedGoogle Scholar
  7. 7.
    Brasme JF, Mille F, Benhayoun M, Bavoux F, Faye A, Teissier N et al (2008) Uncomplicated outcome after an accidental overdose of nevirapine in a newborn. Eur J Pediatr 167(6):689–90, Epub 2007 Jun 29PubMedGoogle Scholar
  8. 8.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC (2012) 2011 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 50:911–1164Google Scholar
  9. 9.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC (2011) 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 49:910–941Google Scholar
  10. 10.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL (2010) 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 48(10):979–1178Google Scholar
  11. 11.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL (2009) 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 47(10):911–1084Google Scholar
  12. 12.
    Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE (2008) 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 46(10):927–1057Google Scholar
  13. 13.
    William WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, Borys D, May ME (2002) Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System (2003). Am J Emergency Med 21(5):353–421Google Scholar
  14. 14.
    Hervey PS, Perry CM (2000) Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60(2):447–479PubMedGoogle Scholar
  15. 15.
    Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308):727–732PubMedGoogle Scholar
  16. 16.
    Clay PG (2002) The abacavir hypersensitivity reaction: a review. Clin Ther 24(10):1502–1514PubMedGoogle Scholar
  17. 17.
    D:A:D Study Group, Sabin CA, Worm SW, Weber R et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371(9622):1417PubMedGoogle Scholar
  18. 18.
    Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R et al (2011) Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 25(16):1993–2004PubMedGoogle Scholar
  19. 19.
    Moreno S, Hernández B, Dronda F (2007) Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. Drugs 67(10):1441–1462PubMedGoogle Scholar
  20. 20.
    Floridia M, Vella S, Seeber AC, Tomino C, Fragola V, Weimer LE et al (1997) A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection. J Infect Dis 175(2):255–264PubMedGoogle Scholar
  21. 21.
    Saag MS (2006) Emtricitabine. a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 42(1):126–131, Epub 2005. Nov 23PubMedGoogle Scholar
  22. 22.
    Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration [updated 2012 July 23; cited 2012 Dec 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf)
  23. 23.
    Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A et al (1999) The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13(16):2239–2250PubMedGoogle Scholar
  24. 24.
    Johnson MA, Verpooten GA, Daniel MJ, Plumb R, Moss J, Van Caesbroeck D et al (1998) Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 46(1):21–27PubMedCentralPubMedGoogle Scholar
  25. 25.
    Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration. [updated 2011 Nov 18; cited 2012 Dec 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020564s031,020596s030lbl.pdf
  26. 26.
    Hurst M, Noble S (1999) Stavudine: an update of its use in the treatment of HIV infection. Drugs 58(5):919–949PubMedGoogle Scholar
  27. 27.
    Chapman T, McGavin J, Noble S (2003) Tenofovir disoproxil fumarate. Drugs 63(15):1597–1608PubMedGoogle Scholar
  28. 28.
    Young J, Scha¨ fer J, Fux CA, Furrer H, Bernasconni E, Vernazza P, Calmy A, Cavassani M, Weber R, Battegay M, Bucher HC, Swiss HIV Cohort Study (2012) Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 26(5):567–575PubMedGoogle Scholar
  29. 29.
    Mathew G, Knaus SJ (2006) Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 21(11):C3–C5PubMedCentralPubMedGoogle Scholar
  30. 30.
    Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C et al (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26(7):867–875PubMedCentralPubMedGoogle Scholar
  31. 31.
    Dudley MN (1995) Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 171:S99–112PubMedGoogle Scholar
  32. 32.
    Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A et al (1995) A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 333(7):408–413PubMedGoogle Scholar
  33. 33.
    Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22(6):685–708PubMedGoogle Scholar
  34. 34.
    Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2(10):812–822PubMedGoogle Scholar
  35. 35.
    Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JA, Koopmans PP (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 12(14):1735–1744PubMedGoogle Scholar
  36. 36.
    Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18(2):137–151PubMedGoogle Scholar
  37. 37.
    Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ (2001) Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol 177(1):54–58PubMedGoogle Scholar
  38. 38.
    Scruggs ER, Dirks Naylor AJ (2008) Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 82(2):83–88, Epub 2008May 27PubMedGoogle Scholar
  39. 39.
    Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22(8):911–936, discussion 898PubMedGoogle Scholar
  40. 40.
    Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337(8740):508–510PubMedGoogle Scholar
  41. 41.
    Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322(16):1098–1105PubMedGoogle Scholar
  42. 42.
    Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, Jay CA (1994) Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 35(4):482–487PubMedGoogle Scholar
  43. 43.
    Peters BS, Winer J, Landon DN, Stotter A, Pinching AJ (1993) Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 86(1):5–15PubMedGoogle Scholar
  44. 44.
    Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P, Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) (2005) Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 40(2):121–131PubMedGoogle Scholar
  45. 45.
    Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S et al (2001) Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15(14):1801–1809PubMedGoogle Scholar
  46. 46.
    McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE, Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL, ESS40010) Study Team (2004) Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38(2):263–270, Epub 2003 Dec 18PubMedGoogle Scholar
  47. 47.
    Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA et al (1994) Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS Cohort Study, 1985–1992. Neurology 44(10):1892–1900PubMedGoogle Scholar
  48. 48.
    McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4(9):543–555PubMedGoogle Scholar
  49. 49.
    Wulff EA, Wang AK, Simpson DM (2000) HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59(6):1251–1260PubMedGoogle Scholar
  50. 50.
    Cornblath DR, McArthur JC (1988) Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 38(5):794–796PubMedGoogle Scholar
  51. 51.
    Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, So Y, Marra CM, Diaz-Arrastia R, Shriver S, Millar L, Clifford DB, ACTG A547 Study Group (2006) HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 66(11):1679–1687Google Scholar
  52. 52.
    Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM et al (1993) 2’, 3’-Didehydro-3’-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 167(1):21–29PubMedGoogle Scholar
  53. 53.
    Simpson DM, Tagliati M (1995) Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune defic Syndr Hum Retrovirol 9(2):153–161PubMedGoogle Scholar
  54. 54.
    Cherry CL, Gahan ME, McArthur J, Lewin SR, Hoy JF, Wesseling SL (2002) Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30(3):271–277PubMedGoogle Scholar
  55. 55.
    Russel JW, Cupler EJ, Dalakas MC (1995) Electrophysiological and pathological changes in 2’,3’-dideoxycytidine (ddC)-induced myopathy in an animal model. Ann Neurol 38:306Google Scholar
  56. 56.
    Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6(1):14–20PubMedGoogle Scholar
  57. 57.
    Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA (2001) Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 33(11):1914–1921, Epub 2001Oct 24PubMedGoogle Scholar
  58. 58.
    Bartlett K, Eaton S (2004) Mitochondrial beta-oxidation. Eur J Biochem 271(3):462–469PubMedGoogle Scholar
  59. 59.
    Lai KK, Gang DL, Zawacki JK, Cooley TP (1991) Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med 115(4):283–284PubMedGoogle Scholar
  60. 60.
    Calza L, Manfredi R, Chiodo F (2005) Hyperlactatemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 24(1):5–15PubMedGoogle Scholar
  61. 61.
    Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC (2000) Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31(1):162–166, Epub 2000 Jul 26PubMedGoogle Scholar
  62. 62.
    John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ et al (2001) Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15(6):717–723PubMedGoogle Scholar
  63. 63.
    Falcó V, Rodríguez D, Ribera E, Martínez E, Miró JM, Domingo P, Diazaraque R et al (2002) Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 34(6):838–846, Epub 2002, Feb 13PubMedGoogle Scholar
  64. 64.
    Lactic Acidosis International Study Group (2007) Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 21(18):2455–2464Google Scholar
  65. 65.
    Miro O, Lopez S, Martinez E, Pedrol E, Milinkovic A, Deig E et al (2004) Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 39(5):710–716, Epub 2004, Aug 13PubMedGoogle Scholar
  66. 66.
    Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46(3):716–723PubMedCentralPubMedGoogle Scholar
  67. 67.
    Brinkman K (2001) Management of hyperlactatemia: no need for routine lactate measurements. AIDS 15(6):795–797PubMedGoogle Scholar
  68. 68.
    Fouty B, Frerman F, Reves R (1998) Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352(9124):291–292PubMedGoogle Scholar
  69. 69.
    Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF (2000) l-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 14(4):472–473PubMedGoogle Scholar
  70. 70.
    Venhoff N, Setzer B, Lebrecht D, Walker UA (2002) Dietary supplements in the treatment of nucleoside reverse transcriptase inhibitor-related mitochondrial toxicity. AIDS 16(5):800–802PubMedGoogle Scholar
  71. 71.
    Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L et al (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346(11):811–820PubMedGoogle Scholar
  72. 72.
    Havlir D, McLaughlin MM, Richman DD (1995) A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 172(5):1379–1383PubMedGoogle Scholar
  73. 73.
    Sheran M (2005) The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. HIV Clin Trials 6(3):158–168PubMedGoogle Scholar
  74. 74.
    Nazziwa R, Sekadde M, Kanyike F, Wobudeya E, Nabukeera-Barungi N (2012) Efavirenz poisoning in a 12 year old HIV negative African boy. Pan Afr Med J 12:86. 12:86, Epub 2012 Jul 26Google Scholar
  75. 75.
    Blanch J, Corbella B, García F, Parellada E, Gatell JM (2001) Manic syndrome associated with efavirenz overdose. Clin Infect Dis 33(2):270–271PubMedGoogle Scholar
  76. 76.
    Pasticci MB, Bonora S, DICandilo F, Lapalorcia LM, Palladino N, Baldelli F (2007) Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis. J Chemother 19(1):110PubMedGoogle Scholar
  77. 77.
    Deeks ED, Keating GM (2008) Etravirine. Drugs 68(16):2357–2372PubMedGoogle Scholar
  78. 78.
    Scott LJ, Perry CM (2000) Delavirdine: a review of its use in HIV infection. Drugs 60(6):1411–1444PubMedGoogle Scholar
  79. 79.
    Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C et al (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, The Advanced HIV Disease Ritonavir Study Group. Lancet 351(9102):543–549PubMedGoogle Scholar
  80. 80.
    Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7):F51–F58PubMedGoogle Scholar
  81. 81.
    Kotler DP (2008) HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 49(Suppl 2):S79–S85PubMedGoogle Scholar
  82. 82.
    Stanley TL, Joy T, Hadigan CM, Liebau JG, Makimura H, Chen CY et al (2009) Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 23(11):1349–1357PubMedCentralPubMedGoogle Scholar
  83. 83.
    DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W, Thiebaut R, DeWit S, Kirk O, Fontas E, Law S, Phillips A, Lundgren JD (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356(17):1723–1735Google Scholar
  84. 84.
    Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348(8):702–710PubMedGoogle Scholar
  85. 85.
    Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA et al (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165(10):1179–1184PubMedGoogle Scholar
  86. 86.
    Hruz PW (2008) HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS 3(6):660–665PubMedCentralPubMedGoogle Scholar
  87. 87.
    Vyas AK, Koster JC, Tzekov A, Hruz PW (2010) Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice. J Biol Chem 285(47):36395–36400, Epub 2010 Sep 23PubMedCentralPubMedGoogle Scholar
  88. 88.
    Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353(9170):2093–2099PubMedGoogle Scholar
  89. 89.
    Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338(18):1281–1292PubMedGoogle Scholar
  90. 90.
    Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA et al (2008) Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 9(1):1–10PubMedGoogle Scholar
  91. 91.
    Roberts DM, Ray JE, Buckley NA (2008) Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir/ritonavir poisoning in a HIV-positive patient. AIDS 22(6):792–793PubMedGoogle Scholar
  92. 92.
    McKeage K, Perry CM, Keam SJ (2009) Darunavir: a review of its use in the management of HIV infection in adults. Drugs 69(4):477–503PubMedGoogle Scholar
  93. 93.
    Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM et al (2009) Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23(13):1679–1688PubMedGoogle Scholar
  94. 94.
    Clotet B, Bellos N, Molina JM, POWER 1 and 2 study groups et al (2007) Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369(9568):1169–1178PubMedGoogle Scholar
  95. 95.
    Rakhmanina NY, Neely MN, Capparelli EV (2012) High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. Ther Drug Monit 34(3):237–241PubMedCentralPubMedGoogle Scholar
  96. 96.
    Plosker GL, Noble S (1999) Indinavir: a review of its use in the management of HIV infection. Drugs 58(6):1165–1203PubMedGoogle Scholar
  97. 97.
    Huynh J, Hever A, Tom T, Sim JJ (2011) Indinavir-induced nephrolithiasis three and one-half years after cessation of indinavir therapy. Int Urol Nephrol 43(2):571–573, Epub 2010May 11PubMedGoogle Scholar
  98. 98.
    Crixivan [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc; 2004Google Scholar
  99. 99.
    Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C et al (1997) Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127(2):119–125PubMedGoogle Scholar
  100. 100.
    Lehman HP, Benson JO, Beninger PR, Anderson CA, Blumenthal SJ, Sharrar RG (2003) A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiol Drug Saf 12(6):449–457PubMedGoogle Scholar
  101. 101.
    Orman JS, Perry CM (2008) Tipranavir: a review of its use in the management of HIV infection. Drugs 68(10):1435PubMedGoogle Scholar
  102. 102.
    Drugs @ FDA [webpage on the Internet]. FDA approved drug products. Silver Spring, MD: U.S. Food and Drug Administration. [updated 2012 Feb 17; cited 2012 Dec 1]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021814s013,022292s006lbl.pdf
  103. 103.
    Dong BJ, Cocohoba JM (2006) Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 40(7–8):1311–1321, Epub 2006Jun 20PubMedGoogle Scholar
  104. 104.
    Justice AC, Zingmond DS, Gordon KS, Fultz SL, Goulet JL, King JT Jr, Bravata DM, Valdez H, Kraft M, Mattocks KM, Veterans Aging Cohort Study Project Team (2008) Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis 47(9):1226–1230Google Scholar
  105. 105.
    Graff J, von Hentig N, Kuczka K, Angioni C, Gute P, Klauke S et al (2008) Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother 61(2):394–399, Epub 2007 Dec 21PubMedGoogle Scholar
  106. 106.
    Croom KF, Dhillon S, Keam SJ (2009) Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 69(8):1107–1140PubMedGoogle Scholar
  107. 107.
    McDonald C, Uy J, Hu W, Wirtz V, Juethner S, Butcher D et al (2012) Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 26(5):259264, Epub 2012Mar 9Google Scholar
  108. 108.
    Bardsley-Elliot A, Plosker GL (2000) Nelfinavir: an update on its use in HIV infection. Drugs 59(3):581–620PubMedGoogle Scholar
  109. 109.
    Arvieux C, Tribut O (2005) Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65(5):633–659PubMedGoogle Scholar
  110. 110.
    Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC (2001) Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potentially synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183(7):1121–1125, Epub 2001 Mar 8PubMedGoogle Scholar
  111. 111.
    Dando TM, Perry CM (2003) Enfuvirtide. Drugs 63(24):2755–2766PubMedGoogle Scholar
  112. 112.
    MacArthur RD, Novak RM (2008) Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47(2):236–241PubMedGoogle Scholar
  113. 113.
    Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J et al (2010) Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCRt-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 55(5):558–564PubMedCentralPubMedGoogle Scholar
  114. 114.
    Palmisano L (2007) Role of integrase inhibitors in the treatment of HIV disease. Expert Rev Anti Infect Ther 5(1):67–75PubMedGoogle Scholar
  115. 115.
    Hicks C, Gulick RM (2009) Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 48(7):931–939PubMedGoogle Scholar
  116. 116.
    Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA et al (2011) Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 1222:83–89PubMedGoogle Scholar

Copyright information

© American College of Medical Toxicology 2013

Authors and Affiliations

  • Asa M. Margolis
    • 1
  • Harry Heverling
    • 2
  • Paul A. Pham
    • 2
  • Andrew Stolbach
    • 3
    Email author
  1. 1.Department of Emergency MedicineJohns Hopkins University School of MedicineNew YorkUSA
  2. 2.Division of Infectious DiseasesJohns Hopkins University, School of MedicineNew YorkUSA
  3. 3.Department of Emergency MedicineJohns Hopkins University, School of MedicineNew YorkUSA

Personalised recommendations